Latest Articles
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab - OncLive
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab OncLive
Published: Dec. 26, 2025, 1:19 p.m.
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations - OncLive
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations OncLive
Published: Dec. 26, 2025, 1:19 p.m.
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... - MSN
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... MSN
Published: Dec. 25, 2025, 7:50 p.m.
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer - Targeted Oncology
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer Targeted Oncology
Published: Dec. 23, 2025, 2:07 p.m.
First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer - Investing.com Nigeria
First patient dosed in phase 3 trial evaluating ENHERTU in endometrial cancer Investing.com Nigeria
Published: Dec. 23, 2025, 2:36 a.m.
Nab-Sirolimus Plus Letrozole Shows Early Activity in Advanced/Recurrent Endometrioid Endometrial Cancer - OncLive
Nab-Sirolimus Plus Letrozole Shows Early Activity in Advanced/Recurrent Endometrioid Endometrial Cancer OncLive
Published: Dec. 22, 2025, 7:02 p.m.
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology
Published: Dec. 22, 2025, 1:15 p.m.
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial - marketscreener.com
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial marketscreener.com
Published: Dec. 22, 2025, 11:40 a.m.
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer - Nasdaq
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer Nasdaq
Published: Dec. 22, 2025, 11:34 a.m.
Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer - Nature
Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer Nature
Published: Dec. 22, 2025, 10:55 a.m.
Link copied to clipboard!